554 related articles for article (PubMed ID: 18996676)
1. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
2. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
Jevtović Dj; Ranin J; Salemović D; Pesić I; Dragović G; Zerjav S; Djurković-Djaković O
Biomed Pharmacother; 2008 Jan; 62(1):21-5. PubMed ID: 17223307
[TBL] [Abstract][Full Text] [Related]
5. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
8. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
[TBL] [Abstract][Full Text] [Related]
9. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome.
Gazzaruso C; Bruno R; Garzaniti A; Giordanetti S; Fratino P; Sacchi P; Filice G
J Hypertens; 2003 Jul; 21(7):1377-82. PubMed ID: 12817187
[TBL] [Abstract][Full Text] [Related]
10. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
[TBL] [Abstract][Full Text] [Related]
11. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
12. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
[TBL] [Abstract][Full Text] [Related]
13. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
[TBL] [Abstract][Full Text] [Related]
14. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.
Boulassel MR; Morales R; Murphy T; Lalonde RG; Klein MB
J Med Virol; 2006 Sep; 78(9):1158-63. PubMed ID: 16847953
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk--results from the VALSIM Study.
Fiuza M; Cortez-Dias N; Martins S; Belo A;
Rev Port Cardiol; 2008 Dec; 27(12):1495-529. PubMed ID: 19280993
[TBL] [Abstract][Full Text] [Related]
16. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study.
Kim JY; Zaoutis T; Chu J; Zhao H; Rutstein R
Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):589-94. PubMed ID: 19402031
[TBL] [Abstract][Full Text] [Related]
17. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.
Hansen BR; Petersen J; Haugaard SB; Madsbad S; Obel N; Suzuki Y; Andersen O
HIV Med; 2009 Jul; 10(6):378-87. PubMed ID: 19490178
[TBL] [Abstract][Full Text] [Related]
19. Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls.
Bergersen BM; Schumacher A; Sandvik L; Bruun JN; Birkeland K
Scand J Infect Dis; 2006; 38(8):682-9. PubMed ID: 16857615
[TBL] [Abstract][Full Text] [Related]
20. Cervical lipomatosis in HIV-infected patients: a case-control study.
Palacios R; Galindo MJ; Arranz JA; Lozano F; Estrada V; Rivero A; Morales D; Asensi V; del Arco A; Muñoz A; Santos J
HIV Med; 2007 Jan; 8(1):17-21. PubMed ID: 17305927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
